Drug Discovery – Talk Bio

Friday Five: Lilly Expands Zepbound’s DTC Reach, NVIDIA Powers Drug Discovery at Lilly and Verily, and OpenAI Advances Pharma AI Initiatives

2 weeks ago talkbio0Tagged AI supercomputer, direct-to-consumer ( DTC ), Drug Discovery, federated learning, LillyDirect, NVIDIA, OpenAI, Pharma AI, TuneLab, Walmart partnership, Zepbound

LillyDirect; Zepbound; Direct-to-consumer (DTC); NVIDIA; AI supercomputer; Verily; OpenAI; Pharma AI; Drug discovery; Walmart partnership; TuneLab; Federated learning

Eli Lilly and Nvidia to Build Pharma’s Largest AI Supercomputer for Drug Discovery

2 weeks ago talkbio0Tagged Artificial Intelligence, biomedical foundation models, Blackwell Ultra GPU, Clinical Trials, Drug Discovery, Drug Industry, eli lilly, high-performance computing, NVIDIA, supercomputer

Eli Lilly; Nvidia; supercomputer; AI; drug discovery; Blackwell Ultra GPU; clinical trials; biomedical foundation models; pharmaceutical industry; high-performance computing

From JP Morgan to the Next Wave: What’s Driving Biotech in 2026

2 weeks ago talkbio0Tagged 2026, Artificial Intelligence, Drug Discovery, Hematology (discipline), Investments, J.P. Morgan Healthcare Conference, M&A activity, Neoplasms, Neuropsychology, regulatory science, trends qualifier

J.P. Morgan Healthcare Conference; biotech trends 2026; M&A activity; oncology; neuropsychology; hematology; artificial intelligence; drug discovery; investment; regulatory science

Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion

2 months ago talkbio0Tagged Autoimmune Diseases, Collaboration, Drug Discovery, Immunology, molecular glue degraders, Monte Rosa Therapeutics, Novartis, QuEEN, royalties, upfront payment

Novartis; Monte Rosa Therapeutics; molecular glue degraders; $5.7 billion deal; drug discovery; immunology; QuEEN platform; autoimmune diseases; upfront payment; royalties; collaboration

Novartis Expands Degrader-Focused Collaboration with Monte Rosa Through Major Molecular Glue Deal

2 months ago talkbio0Tagged AI/ML-enabled product, Collaboration, Drug Discovery, engine, immune-mediated diseases, milestone payments, molecular glue degraders, Monte Rosa Therapeutics, MRT-6160, Novartis, VAV1 protein

Novartis; Monte Rosa Therapeutics; molecular glue degraders; MRT-6160; VAV1 protein; immune-mediated diseases; drug discovery; collaboration; milestone payments; AI/ML-enabled product engine

Merck Moves All R&D Operations Out of UK, Citing Unfavorable Environment

2 months ago talkbio0Tagged Biological Science Disciplines, Brexit impact, Drug Discovery, Government, Investments, layoffs, London Bioscience Innovation Centre, Merck, Multiple Sulfatase Deficiency Disease, Relocation of home or business, UK

Merck; MSD; R&D relocation; UK life sciences; drug discovery; Brexit impact; London Bioscience Innovation Centre; Francis Crick Institute; government investment; layoffs

Lilly Opens AI Drug-Discovery Models to Biotechs for Free via TuneLab Platform

2 months ago talkbio0Tagged Antibodies, Artificial Intelligence, biotech startups, Drug Discovery, eli lilly, federated learning, Insitro, Machine Learning, Small Molecule, TuneLab

Eli Lilly; AI drug discovery; TuneLab; biotech startups; machine learning; small molecules; antibodies; data sharing; federated learning; Insitro

IQVIA Laboratories Bioinformatics Solutions Accelerate Genomic Insights for Drug Discovery in Partnership with NVIDIA

2 months ago talkbio0Tagged AI agents, Artificial Intelligence, Bio-Informatics, Drug Discovery, Enterprise, Genome, Genomics, IQVIA, NVIDIA, Precision Medicine

IQVIA; Genomic Insights; Bioinformatics; Drug Discovery; NVIDIA; AI Agents; Genomics; Precision Medicine; AI Enterprise; E360 Genomics

Genentech (Roche) Signs $420 Million Deal With OMass Therapeutics for Preclinical IBD Program

2 months ago talkbio0Tagged Drug Discovery, genentech, Inflammatory Bowel Diseases, milestone payments, OdyssION platform, OMass, Partnership, preclinical program, Roche (company), small molecule therapy

Genentech; Roche; OMass Therapeutics; inflammatory bowel disease (IBD); preclinical program; biotech partnership; OdyssION platform; small molecule therapy; drug discovery; milestone payments

Recent Advances: AI in Life Sciences—Reimagining Teams, Technology, and Partnerships

3 months ago talkbio0Tagged Artificial Intelligence, Biological Science Disciplines, Data Integration, Drug Discovery, Generative AI, language models, Precision Medicine, strategic partnerships, team transformation, technology innovation

AI in life sciences; generative AI; large language models; team transformation; technology innovation; strategic partnerships; drug discovery; personalized medicine; data integration